INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer’s readout. Lead asset XPro1595’s mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback